Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKLIXZ)

Drug Name
Tetrabromocinnamic acid Drug Info
Synonyms TBCA; tetrabromocinnamic acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
16760346
CAS Number
CAS 934358-00-6
TTD Drug ID
DMKLIXZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Casein kinase II (CSNK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CIGB-300 DM0Q6CM Cervical cancer 2C77.0 Phase 3 [2]
CX-4945 DMWE7B9 Coronavirus infection 1D92 Phase 2 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Casein kinase II (CSNK2) TTZ5NI7 NOUNIPROTAC Inhibitor [1]

References

1 Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2007 Jan 2;8(1):129-39.
2 Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models. Mol Clin Oncol. 2014 Nov;2(6):935-944.
3 CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia. 2013 Oct;27(10):2094-6.